Skip to main content

Table 6 Plasma pharmacokinetic parameters for PR-104A metabolites, cycle 1 day 1

From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

  

Cmax(μM)

AUC (μM h)

t1/2(h)

Dose-level (mg/m 2 )

n

PR-104G

PR-104H

PR-104M

PR-104S1

PR-104G

PR-104H

PR-104M

PR-104S1

PR-104G

PR-104H

PR-104M

PR-104S1

135

2

1.66

0.66

0.05

0.06

1.67

0.79

0.08

0.10

0.25

0.48

0.53

0.76

270

6

3.02 (2.12)

0.68 (0.29)

0.06 (0.02)

0.14 (0.09)

3.96 (3.81)

0.81 (0.37)

0.11 (0.05)

0.25 (0.17)

0.40 (0.22)

0.51 (0.12)

0.88 (0.43)

1.09 (0.51)

540

6

11.27 (8.07)

0.49 (0.17)

0.07 (0.02)

0.20 (0.08)

13.85 (12.01)

0.63 (0.26)

0.11 (0.04)

0.29 (0.13)

0.38 (0.14)

0.41 (0.12)

0.56 (0.15)

0.59 (0.23)

675

7

8.71 (4.52)

0.51 (0.27)

0.08 (0.05)

0.36 (0.25)

11.9 (7.4)

0.71 (0.32)

0.13 (0.06)

0.49 (0.45)

0.49 (0.17)

0.74 (0.37)

0.75 (0.28)

0.68 (0.12)

900

4

7.81 (3.92)

0.39 (0.16)

0.07 (0.03)

0.31 (0.13)

11.19 (6.54)

0.69 (0.26)

0.16 (0.08)

0.64 (0.25)

0.68 (0.18)

0.85 (0.09)

0.88 (0.11)

0.79 (0.15)

  1. Values are the mean (SD)